Zoetis Inc. (NYSE:ZTS) Shares Sold by Trust Co. of Vermont

Trust Co. of Vermont decreased its holdings in Zoetis Inc. (NYSE:ZTS) by 12.2% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 855 shares of the company’s stock after selling 119 shares during the quarter. Trust Co. of Vermont’s holdings in Zoetis were worth $169,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors also recently bought and sold shares of the business. Price T Rowe Associates Inc. MD lifted its stake in shares of Zoetis by 31.0% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 13,716,681 shares of the company’s stock valued at $2,707,262,000 after purchasing an additional 3,244,074 shares during the period. Wellington Management Group LLP increased its holdings in Zoetis by 2.5% in the third quarter. Wellington Management Group LLP now owns 12,344,692 shares of the company’s stock valued at $2,147,730,000 after buying an additional 297,044 shares in the last quarter. Capital World Investors lifted its position in shares of Zoetis by 0.6% during the 4th quarter. Capital World Investors now owns 9,064,158 shares of the company’s stock valued at $1,788,988,000 after acquiring an additional 57,798 shares during the period. Northern Trust Corp boosted its stake in shares of Zoetis by 3.3% during the 3rd quarter. Northern Trust Corp now owns 6,143,258 shares of the company’s stock worth $1,068,804,000 after acquiring an additional 196,771 shares in the last quarter. Finally, Norges Bank acquired a new stake in shares of Zoetis in the 4th quarter worth approximately $980,646,000. Institutional investors and hedge funds own 92.80% of the company’s stock.

Insiders Place Their Bets

In other news, EVP Roxanne Lagano sold 923 shares of the company’s stock in a transaction dated Thursday, April 18th. The shares were sold at an average price of $151.17, for a total transaction of $139,529.91. Following the completion of the transaction, the executive vice president now owns 14,800 shares of the company’s stock, valued at approximately $2,237,316. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. 0.16% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

ZTS has been the subject of several research reports. Barclays reduced their price objective on Zoetis from $260.00 to $230.00 and set an “overweight” rating for the company in a report on Tuesday, April 23rd. The Goldman Sachs Group cut their price target on Zoetis from $223.00 to $196.00 and set a “buy” rating for the company in a research note on Monday, May 6th. Piper Sandler reissued an “overweight” rating and issued a $195.00 price objective (down from $220.00) on shares of Zoetis in a research note on Tuesday, April 16th. StockNews.com cut shares of Zoetis from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, February 20th. Finally, HSBC reduced their price target on shares of Zoetis from $230.00 to $225.00 and set a “buy” rating on the stock in a report on Wednesday, May 8th. Eight research analysts have rated the stock with a buy rating, According to MarketBeat.com, the company has an average rating of “Buy” and an average target price of $211.75.

Zoetis Stock Performance

Shares of NYSE ZTS opened at $170.87 on Tuesday. The company has a 50-day simple moving average of $165.85 and a 200-day simple moving average of $179.50. The company has a debt-to-equity ratio of 1.30, a current ratio of 3.33 and a quick ratio of 1.94. The company has a market cap of $77.97 billion, a PE ratio of 32.92, a price-to-earnings-growth ratio of 2.65 and a beta of 0.89. Zoetis Inc. has a 12 month low of $144.80 and a 12 month high of $201.92.

Zoetis (NYSE:ZTS) last released its earnings results on Thursday, May 2nd. The company reported $1.38 EPS for the quarter, topping the consensus estimate of $1.34 by $0.04. Zoetis had a net margin of 27.38% and a return on equity of 50.34%. The firm had revenue of $2.19 billion during the quarter, compared to analysts’ expectations of $2.14 billion. During the same period in the previous year, the company earned $1.31 EPS. Zoetis’s revenue for the quarter was up 9.5% on a year-over-year basis. On average, equities analysts anticipate that Zoetis Inc. will post 5.76 earnings per share for the current year.

Zoetis Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, September 4th. Investors of record on Thursday, July 18th will be given a dividend of $0.432 per share. The ex-dividend date is Thursday, July 18th. This represents a $1.73 annualized dividend and a yield of 1.01%. Zoetis’s dividend payout ratio (DPR) is presently 33.33%.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.